Mercado mundial de medicamentos oftálmicos: tendencias de la industria y pronóstico hasta 2031

Análisis y tamaño del mercado de medicamentos oftálmicos

El mercado de medicamentos oftálmicos está experimentando un rápido avance, impulsado por métodos y tecnologías de vanguardia. Innovaciones como los implantes de liberación sostenida y la nanotecnología están revolucionando la eficacia del tratamiento y la adherencia del paciente. Este crecimiento responde a un aumento global de los trastornos oculares; el informe de octubre de 2021 de la Organización Mundial de la Salud destacó que casi 2.200 millones de personas padecen problemas de visión. Esta estadística subraya la necesidad urgente de investigación y desarrollo continuos para satisfacer de manera eficaz las crecientes demandas de atención médica. La trayectoria del mercado subraya un cambio fundamental hacia soluciones innovadoras que prometen mejores resultados terapéuticos y una mejor calidad de vida para millones de personas en todo el mundo.                                

El tamaño del mercado mundial de medicamentos oftálmicos se valoró en USD 30,37 millones en 2023 y se proyecta que alcance los USD 53,36 millones para 2031, con una CAGR del 7,3% durante el período de pronóstico de 2024 a 2031. Esto indica que el valor del mercado. Además de los conocimientos sobre escenarios de mercado como el valor de mercado, la tasa de crecimiento, la segmentación, la cobertura geográfica y los principales actores, los informes de mercado seleccionados por Data Bridge Market Research también incluyen un análisis profundo de expertos, epidemiología de pacientes, análisis de cartera, análisis de precios y marco regulatorio.

Alcance del informe y segmentación del mercado

Definición de mercado

Los medicamentos oftálmicos son medicamentos diseñados para tratar afecciones oculares. Vienen en diversas formas, como gotas para los ojos, ungüentos o geles. Estos medicamentos se utilizan para aliviar síntomas como sequedad, picazón o infecciones en los ojos. Algunos medicamentos oftálmicos también se recetan para tratar afecciones como el glaucoma o la inflamación. La aplicación adecuada y el cumplimiento de las instrucciones de dosificación son cruciales para su eficacia.            

Dinámica del mercado de medicamentos oftálmicos

Conductores

• Aumento de la prevalencia de enfermedades oculares

La creciente prevalencia de enfermedades oculares como el glaucoma, las cataratas , la retinopatía diabética y la degeneración macular relacionada con la edad está impulsando significativamente la demanda de medicamentos oftálmicos. Por ejemplo, el aumento de los casos de retinopatía diabética, impulsado por la epidemia mundial de diabetes, requiere tratamientos más avanzados, lo que impulsa el mercado. En consecuencia, el creciente grupo de pacientes con estas afecciones está impulsando el crecimiento del mercado de terapias oftálmicas innovadoras y efectivas.

• Avances tecnológicos en la administración de fármacos

Los avances tecnológicos en la administración de fármacos, como los implantes de liberación sostenida y las formulaciones de nanopartículas, mejoran significativamente la eficacia y el cumplimiento del tratamiento por parte del paciente con los fármacos oftálmicos. Por ejemplo, los implantes de liberación sostenida para el glaucoma proporcionan un tratamiento constante durante meses, lo que reduce la necesidad de utilizar gotas oftálmicas con frecuencia. Estas innovaciones mejoran los resultados del tratamiento y la comodidad, lo que impulsa el mercado de los fármacos oftálmicos al satisfacer las necesidades de los pacientes de manera más eficaz y ampliar las opciones de tratamiento.

Oportunidades

• Programas de concientización y detección crecientes

Growing awareness about eye health and expanded screening programs have led to earlier diagnosis and treatment of eye conditions, significantly fueling the demand for ophthalmic drugs. For instance, initiatives such as World Glaucoma Week have increased public awareness, prompting more people to undergo regular eye check-ups. This proactive approach results in timely intervention, thereby driving the market for ophthalmic drugs as more individuals seek treatment for newly diagnosed conditions.

• Government Initiatives and Policies

Government initiatives and policies, such as subsidies and public health campaigns, are instrumental in reducing the burden of eye diseases, thereby driving market growth for ophthalmic drugs. For instance, the U.S. government's Healthy People 2030 initiative aims to improve eye health through preventive services and education, increasing the demand for treatments. Such supportive measures facilitate better access to ophthalmic care and stimulate the market's expansion. 

Restraints/Challenges

• Complex Manufacturing Processes

Complex manufacturing processes in the ophthalmic drugs market pose significant challenges. High precision is essential in drug formulation and production, demanding advanced technologies and skilled personnel. Additionally, stringent sterility and stability requirements must be met to ensure product safety and efficacy. These factors lead to increased production costs and time, further complicating the development and availability of ophthalmic drug. 

• High Development Costs

High development costs are a significant restraint in the ophthalmic drugs market. Expensive research and development investments and the high cost of clinical trials and regulatory compliance create substantial financial barriers. These costs hinder the market by limiting the ability of smaller companies to compete and slowing the introduction of new drugs. Consequently, innovation is stifled, and market growth is restricted due to these financial burdens.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In February 2023, Bayer AG submitted aflibercept 8 mg for regulatory approval in the European Union, targeting two major retinal diseases. This submission is a significant step for Bayer, as aflibercept is expected to provide an advanced treatment option for patients suffering from these conditions, potentially improving visual outcomes and quality of life for many individuals across Europe
• In January 2023, Bausch Health Companies, Inc. launched PreserVision AREDS 2 Formula minigel eye vitamins in the United States. This product is specifically formulated for individuals with moderate-to-advanced Age-related Macular Degeneration (AMD). The mini gel format offers an easier-to-swallow alternative to traditional eye vitamins, aiming to enhance patient compliance and support eye health effectively
• In April 2022, Sandoz, a Novartis company, introduced its generic combination eyedrop brimonidine tartrate/timolol maleate ophthalmic solution 0.2%/0.5% in the United States. This product is an AB-rated generic equivalent to AbbVie's COMBIGAN and is designed to lower intraocular pressure in patients with ocular hypertension. The launch provides a more affordable treatment option while maintaining efficacy and safety standards
• In March 2022, Théa Pharma acquired seven branded ophthalmic products from Akorn Operating Company LLC. This strategic acquisition enhances Théa Pharma's portfolio and strengthens its position in the U.S. market. The newly acquired products are expected to meet the diverse needs of eye care specialists, allowing Théa Pharma to offer comprehensive solutions for various ophthalmic conditions

Ophthalmic Drugs Market Scope

The market is segmented on the basis of drugs, disease, dosage form, route of administration, product type, product, end-users, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drugs

• Anti-Inflammatory
  • NSAID’s
  • Steroied
• Anti-Infective
  • Anti-Fungal
  • Anti-Bacterial
  • Others
•  Anti-Glaucoma
  • Alpha Agonist
  • Beta Blockers
  • Prostaglandin Analogs
  • Combined Medication
  • Others
•  Anti-Allergy
•  Anti-Vascular Endothelial Growth Factor
•  Others

 Disease

• Dry Eye
• Allergies
• Glaucoma
• Eye Infection
• Infection
• Retinal Disorders
• Uveitis
  • Gels
  • Eye Solutions and Suspensions
  • Capsules and Tablets
  • Eye Drops
  • Ointments
• Others

 Dosage Form

• Gels
• Eye Solutions and Suspensions
• Capsules and Tablets
• Eye Drops
• Ointments

 Route of Administration

• Topical
  • Retinal Disorders
  • Subconjunctival
  • Intravitreal
  • Retrobulbar
  • Intracameral
• Local Ocular
• Systemic

 Product Type

• Prescription Drugs
• OTC

 Product

• Branded Drugs
• Generic Drugs

 End-Users

• Hospitals
• Specialty Clinics
• Others

 Distribution Channel

• Direct
• Indirect

Ophthalmic Drugs Market Regional Analysis/Insights

The market is analysed and market size insights and trends are provided by country, drugs, disease, dosage form, route of administration, product type, product, end-users, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing positive growth in the ophthalmic drugs market due to the increased prevalence of eye diseases and rising awareness. Research and development by major players such as Alcon, Pfizer Inc., and Bausch and Lomb, along with frequent product launches, further boost regional growth.

Asia-Pacific is expected to dominate the ophthalmic drugs market due to its large patient base, high disease incidence, and the rise of local companies. Strategic initiatives by major players further bolster regional growth prospects in this vital healthcare sector.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and Ophthalmic Drugs Market Share Analysis

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Some of the major players operating in the market are:

• Akorn Operating Company LLC. (U.S.)
• Johnson & Johnson Services, Inc.(U.S.)
• Mitotech Ltd  (Germany)
• AbbVie Inc. (U.S.)
• Santen Pharmaceutical Co., Ltd. (Japón).
• Industrias farmacéuticas Teva Ltd. (Israel)
• Bausch Health Companies Inc. (Canadá).
• AERIE PHARMACEUTICALS, INC. (EE. UU.)
• Novartis AG (Suiza)
• Merck & Co. Inc. (Estados Unidos)
• Bayer AG (Alemania)
• F. Hoffmann-La Roche Ltd (Suiza)

SKU-52898